Stock listing
BOATS:RNAZ TransCode Therapeutics, Inc. Stock
US listing (BOATS) of TransCode Therapeutics, Inc. · home listing NASDAQ:RNAZ
Follow TransCode Therapeutics, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:RNAZ
$1.16 USD -0.19 (-13.8%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:RNAZ
- Day range
- $1.01 – $1.35 USDNov 20, 2026
- Volume
- 60,672 sharesNov 20, 2026
- Market cap
- $20.07M USDAt the close on Nov 20, 2026 · price × 17.30M shares outstanding
- 52-week range
- $1.01 – $12.60 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $100,057 USDMedian day 29,017 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:RNAZ · Home | $1.16 USD | -0.185 (-13.8%) | 60,672 | $1.35 | $1.35 | $1.01 | $1.345 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:RNAZ · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.16 | -0.185 | -13.8% | $1.35 | $1.35 | $1.01 | 60,672 | |
| $1.345 | -0.065 | -4.6% | $1.39 | $1.40 | $1.29 | 18,083 | |
| $1.41 | +0.06 | +4.4% | $1.46 | $1.527 | $1.28 | 36,661 | |
| $1.35 | +0.03 | +2.3% | $1.34 | $1.47 | $1.29 | 50,315 | |
| $1.32 | -0.07 | -5.1% | $1.43 | $1.45 | $1.30 | 20,847 | |
| $1.39 | -0.01 | -0.7% | $1.36 | $1.47 | $1.35 | 13,915 | |
| $1.40 | +0.05 | +3.7% | $1.33 | $1.44 | $1.33 | 11,992 | |
| $1.35 | -0.19 | -12.3% | $1.51 | $1.55 | $1.33 | 24,029 | |
| $1.54 | +0.05 | +3.4% | $1.57 | $1.59 | $1.50 | 16,155 | |
| $1.49 | -0.02 | -1.3% | $1.53 | $1.56 | $1.45 | 12,777 | |
| $1.51 | -0.09 | -5.6% | $1.63 | $1.67 | $1.475 | 21,850 | |
| $1.60 | +0.03 | +1.9% | $1.61 | $1.72 | $1.57 | 7,097 | |
| $1.57 | -0.06 | -3.7% | $1.60 | $1.65 | $1.50 | 29,550 | |
| $1.63 | 0.00 | 0.0% | $1.69 | $1.69 | $1.61 | 16,519 | |
| $1.63 | -0.10 | -5.8% | $1.73 | $1.785 | $1.62 | 16,185 | |
| $1.73 | -0.01 | -0.6% | $1.837 | $1.91 | $1.73 | 39,291 | |
| $1.74 | +0.07 | +4.2% | $1.61 | $1.78 | $1.61 | 18,493 | |
| $1.67 | -0.036 | -2.1% | $1.71 | $1.77 | $1.65 | 7,502 | |
| $1.706 | -0.065 | -3.6% | $1.78 | $1.78 | $1.70 | 54,290 | |
| $1.77 | +0.055 | +3.2% | $1.65 | $1.84 | $1.65 | 32,683 | |
| $1.715 | +0.055 | +3.3% | $1.62 | $1.80 | $1.62 | 27,965 | |
| $1.66 | -0.02 | -1.2% | $1.69 | $1.81 | $1.65 | 16,753 | |
| $1.68 | -0.02 | -1.2% | $1.71 | $1.75 | $1.603 | 20,230 | |
| $1.70 | 0.00 | 0.0% | $1.70 | $1.84 | $1.66 | 29,305 | |
| $1.70 | -0.10 | -5.6% | $1.83 | $1.864 | $1.695 | 29,017 | |
| $1.80 | +0.07 | +4.0% | $1.79 | $1.90 | $1.71 | 35,314 | |
| $1.73 | +0.05 | +3.0% | $1.74 | $1.82 | $1.67 | 43,235 | |
| $1.68 | +0.05 | +3.1% | $1.67 | $1.78 | $1.668 | 54,452 | |
| $1.63 | -0.23 | -12.4% | $1.91 | $1.91 | $1.63 | 31,932 | |
| $1.86 | +0.15 | +8.8% | $1.78 | $1.95 | $1.74 | 84,076 | |
| $1.71 | -0.05 | -2.8% | $1.80 | $1.80 | $1.675 | 27,836 | |
| $1.76 | -0.02 | -1.1% | $1.78 | $1.79 | $1.67 | 29,763 | |
| $1.78 | +0.02 | +1.1% | $1.77 | $1.815 | $1.71 | 47,336 | |
| $1.76 | +0.19 | +12.1% | $1.65 | $1.87 | $1.57 | 65,725 | |
| $1.57 | +0.025 | +1.6% | $1.58 | $1.66 | $1.545 | 15,503 | |
| $1.545 | -0.135 | -8.0% | $1.673 | $1.74 | $1.52 | 16,712 | |
| $1.68 | +0.05 | +3.1% | $1.748 | $1.748 | $1.64 | 6,733 | |
| $1.63 | -0.08 | -4.7% | $1.73 | $1.81 | $1.60 | 11,006 | |
| $1.71 | +0.02 | +1.2% | $1.71 | $1.79 | $1.63 | 40,680 | |
| $1.69 | +0.04 | +2.4% | $1.60 | $1.70 | $1.60 | 14,760 | |
| $1.65 | -0.03 | -1.8% | $1.62 | $1.74 | $1.62 | 28,656 | |
| $1.68 | -0.09 | -5.1% | $1.835 | $2.39 | $1.621 | 425,715 | |
| $1.77 | +0.01 | +0.6% | $1.87 | $1.911 | $1.707 | 59,514 | |
| $1.76 | +0.11 | +6.7% | $1.67 | $1.97 | $1.67 | 66,202 | |
| $1.65 | -0.07 | -4.1% | $2.00 | $2.00 | $1.65 | 30,904 | |
| $1.72 | +0.04 | +2.4% | $1.70 | $1.72 | $1.63 | 58,149 | |
| $1.68 | +0.08 | +5.0% | $1.66 | $1.71 | $1.579 | 18,698 | |
| $1.60 | -0.05 | -3.0% | $1.65 | $1.70 | $1.60 | 18,516 | |
| $1.65 | -0.04 | -2.4% | $1.65 | $1.72 | $1.65 | 20,663 | |
| $1.69 | 0.00 | 0.0% | $1.68 | $1.74 | $1.627 | 11,445 | |
| $1.69 | -0.09 | -5.1% | $1.72 | $1.83 | $1.69 | 26,085 | |
| $1.78 | -0.11 | -5.8% | $1.86 | $1.95 | $1.75 | 30,939 | |
| $1.89 | -0.17 | -8.3% | $1.98 | $2.03 | $1.88 | 37,786 | |
| $2.06 | -0.095 | -4.4% | $2.18 | $2.18 | $2.05 | 10,622 | |
| $2.155 | +0.145 | +7.2% | $2.27 | $2.27 | $2.02 | 69,966 | |
| $2.01 | -0.05 | -2.4% | $2.06 | $2.12 | $2.01 | 22,514 | |
| $2.06 | -0.04 | -1.9% | $2.08 | $2.35 | $2.04 | 98,170 | |
| $2.10 | -0.08 | -3.7% | $2.10 | $2.28 | $1.832 | 838,250 | |
| $2.18 | -0.10 | -4.4% | $2.24 | $2.345 | $2.09 | 38,032 | |
| $2.28 | -0.06 | -2.6% | $2.35 | $2.409 | $2.27 | 27,617 | |
| $2.34 | -0.19 | -7.5% | $2.58 | $2.58 | $2.24 | 24,254 | |
| $2.53 | -0.17 | -6.3% | $2.74 | $2.873 | $2.40 | 138,123 | |
| $2.70 | -0.17 | -5.9% | $2.90 | $2.91 | $2.65 | 78,327 | |
| $2.87 | -0.10 | -3.4% | $2.90 | $3.00 | $2.87 | 42,178 | |
| $2.97 | -0.24 | -7.5% | $3.121 | $3.28 | $2.87 | 45,694 |
Splits
4 splits since 2023 · NASDAQ:RNAZ · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-28 | Consolidation | |
| 1-for-33 | Consolidation | |
| 1-for-40 | Consolidation | |
| 1-for-20 | Consolidation |
- Ticker
- BOATS:RNAZ
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
What changed lately
Latest news release · Oct 28, 2026
TransCode Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process Intended to Maximize Value of TTX-MC138 and its Oncology Portfolio
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 44 slides
Latest news
TransCode Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process Intended to Maximize Value of TTX-MC138 and its Oncology Portfolio
Oct 28, 2026
Closed $1.73 (-0.6%) on Oct 29, 2026
TransCode Therapeutics Presents Phase 1a Clinical Data for TTX-MC138 at ESMO Congress 2026
Oct 26, 2026
Closed $1.71 (-3.6%) on Oct 26, 2026
TransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026
Oct 19, 2026
Closed $1.70 (0.0%) on Oct 19, 2026
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
Oct 13, 2026
Closed $1.68 (+3.1%) on Oct 13, 2026
TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up
Sep 28, 2026
Closed $1.71 (+1.2%) on Sep 28, 2026
TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology
Sep 22, 2026
Closed $1.77 (+0.6%) on Sep 22, 2026
TransCode Therapeutics Announces Leadership Transition
Sep 10, 2026
Closed $1.69 (0.0%) on Sep 11, 2026
TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis
Aug 31, 2026
Closed $2.10 (-3.7%) on Aug 31, 2026
TransCode Therapeutics to Host R&D Webcast on June 18, 2026
Jun 8, 2026
Closed $5.09 (-9.1%) on Jun 8, 2026
TransCode Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 19 in the last 12 months · 113 in all · newest Oct 28, 2026 · oldest 2021
- Decks
- 6 decks · latest September 2026
Where TransCode Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:RNAZ · Home listing | NASDAQ | United States | USD |
| BOATS:RNAZ · This page | BOATS | United States | USD |
Valuation
Price/book 0.6× against a median of 1.2×: 4th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $15.44M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 0.6×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.03
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| TransCode Therapeutics, Inc. · NASDAQ:RNAZ | US$20.07M | US$15.44M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 1.03 |
| ZYUS Life Sciences Corporation · TSXV:ZYUS | US$20.92M | US$25.65M | n/a | 98.4× | n/a | n/a | n/a | n/a | -0.02 |
| Xbrane Biopharma AB · OMXSTO:XBRANE | US$20.88M | US$23.48M | n/a | 1.9× | n/a | 0.4× | −49.0% | 0.1× | n/a |
| Vivoryon Therapeutics N.V. · EURONEXT:VVY | US$20.48M | US$17.77M | n/a | n/a | n/a | 11.9× | n/a | 0.1× | n/a |
| Evaxion A/S · NASDAQ:EVAX | US$20.30M | US$13.40M | n/a | 1.8× | n/a | 2.1× | −115.1% | 0.8× | 0.78 |
| Aardvark Therapeutics, Inc. · NASDAQ:AARD | US$20.20M | −US$39.58M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 3.28 |
| GenSight Biologics SA · EURONEXT:SIGHT | US$20.19M | US$32.44M | n/a | 29,573× | n/a | n/a | n/a | n/a | n/a |
| Adicet Bio, Inc. · NASDAQ:ACET | US$20.03M | US$5.02M | n/a | n/a | n/a | 0.2× | n/a | 0.1× | 2.02 |
| IGC Pharma, Inc. · AMEX:IGC | US$19.60M | US$19.19M | n/a | n/a | n/a | 3.0× | n/a | 0.0× | 1.09 |
| Provectus Biopharmaceuticals, Inc. · OTC:PVCT | US$19.12M | US$18.94M | n/a | n/a | n/a | n/a | n/a | n/a | -0.21 |
| LeonaBio, Inc. · NASDAQ:LONA | US$19.03M | −US$12.82M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 1.04 |
| Median of the others | US$20.19M | US$18.35M | 50.1× | 1.2× | −82.1% | 0.1× | 1.04 |
Forecasts
Analysts' consensus from EODHD, read Nov 15, 2026. Not 6ix's view and not investment advice.
- Price target
- 10.00 USD · Analysts' mean
- EPS, year to Dec 2024
- -4.76 · 1 analyst
- Revenue, year to Dec 2024
- 300K · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Philippe Calais | CEO |
| Elizabeth A. Czerepak | CFO, Director |
| John Tattory | Interim CFO |
| Karrie Hilsinger | VP of Clinical Operations |
| Tania Montgomery-Hammon | VP, Business Development |
| Michel Janicot | Consulting Head of Translational Science |
| Zdravka Medarova | Cofounder/Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| Elizabeth A. Czerepak | CFO, Director |
| Erik Manting | Director |
| Jack E. Stover | Director |
| Magda Marquet | Director |
| Philippe Calais | CEO |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 16, 2026 | +6.8% |
| Q2 2026 | Aug 14, 2026 | −9.2% |
| Q1 2026 | May 29, 2026 | +2.7% |
| Q4 2025 | Feb 25, 2026 | +2.7% |
| Q3 2025 | Nov 14, 2025 | +11.8% |
| Q2 2025 | Aug 14, 2025 | −6.9% |
| Q1 2025 | Apr 15, 2025 · After close | −10.4% |
| Q4 2024 | Mar 28, 2025 | −4.8% |
| Q3 2024 | Nov 14, 2024 · After close | −2.9% |
| Q2 2024 | Aug 14, 2024 · After close | +9.7% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 15, 2024 · After close | +9.7% |
| Q4 2023 | Mar 29, 2024 | +1.3% |
| Q3 2023 | Nov 14, 2023 · After close | −9.3% |
| Q2 2023 | Aug 14, 2023 · After close | −1.8% |
| Q1 2023 | May 15, 2023 · After close | −0.4% |
| Q4 2022 | Mar 31, 2023 · After close | +3.4% |
| Q3 2022 | Nov 14, 2022 · After close | +6.7% |
| Q2 2022 | Aug 15, 2022 · After close | +3.1% |
| Q1 2022 | May 16, 2022 · Before open | −8.0% |
| Q4 2021 | Mar 31, 2022 · After close | −1.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 44 slides | September 2026 |
| Investor Presentation (June 2026) | Investor deck | 44 slides | Jun 18, 2026 |
| Investor Presentation (December 2025) | Investor deck | 28 slides | Dec 18, 2025 |
| Investor Presentation (October 2025) | Investor deck | 35 slides | Oct 8, 2025 |
| Investor Presentation (May 2025) | Investor deck | 35 slides | May 23, 2025 |
| Investor Presentation (October 2024) | Investor deck | 19 slides | Oct 28, 2024 |
Financings
| Raise | Date |
|---|---|
| Strategic investment of non-voting Series B convertible preferred stock Announced: US$25M · Tungsten Advisors Dealers: Tungsten Advisors (lead) Buyers: CK Life Sciences Int'l., (Holdings) Inc. (subsidiary) (223.7337 shares of Series B Preferred Stock for $25 million; approximately 91% fully diluted together with the acquisition) Use of proceeds: Primarily to advance clinical development of lead microRNA asset TTX-MC138 into a Phase 2 clinical trial | Oct 9, 2025 |
| Registered direct offering of shares of common stock and warrants Closed: US$10M raised · US$0.98 a share · Warrants at US$0.86 for 60 months · ThinkEquity Dealers: ThinkEquity (lead) Use of proceeds: Product development, including clinical trials of TTX-MC138 and IND-enabling studies, plus working capital and general corporate purposes | Mar 25, 2025 |
| Private placement of shares of common stock with Series C and Series D warrants Update: about US$8M · US$0.377 a share · Warrants at US$0.475 for 60 months · The Benchmark Company, LLC Dealers: The Benchmark Company, LLC (lead) Use of proceeds: General corporate purposes and working capital | Feb 25, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$4.00 a share on Jul 8, 2021.
- Price
- US$4.00 a share
- Shares offered
- 6,250,000 shares of common stock
- Offering size
- US$25 million
- Underwriters' option
- Up to 937,500 more shares
- Listing
- RNAZ on the Nasdaq Capital Market
- Underwriter
- ThinkEquity
- Shares delivered
- On or about Jul 13, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Dec 18, 2020 |
| Filed publicly | Feb 26, 2021 |
| Amended 5 times | Newest Jun 2, 2021 |
| Shares registered with an exchange | Apr 26, 2021 |
| Declared effective by the SEC | Jul 8, 2021 |
| Final prospectus, with the price | Jul 9, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jul 9, 2021 |
| EFFECT · Notice that a registration is effective | Jul 8, 2021 |
| CORRESP · Letter to the SEC | Jul 6, 2021 |
| CORRESP · Letter to the SEC | Jul 6, 2021 |
| S-1/A · Registration statement, amended | Jun 2, 2021 |
| CORRESP · Letter to the SEC | Jun 1, 2021 |
| CORRESP · Letter to the SEC | May 14, 2021 |
| CORRESP · Letter to the SEC | May 6, 2021 |
| CORRESP · Letter to the SEC | May 6, 2021 |
| S-1/A · Registration statement, amended | May 3, 2021 |
All 25 filings
| Filing | Filed |
|---|---|
| CERT · Exchange's certificate of listing | Apr 27, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Apr 26, 2021 |
| CORRESP · Letter to the SEC | Apr 23, 2021 |
| CORRESP · Letter to the SEC | Apr 23, 2021 |
| CORRESP · Letter to the SEC | Apr 16, 2021 |
| S-1/A · Registration statement, amended | Apr 16, 2021 |
| UPLOAD · Letter from the SEC | Apr 14, 2021 |
| S-1/A · Registration statement, amended | Apr 8, 2021 |
| S-1/A · Registration statement, amended | Mar 24, 2021 |
| CORRESP · Letter to the SEC | Mar 11, 2021 |
| S-1 · Registration statement | Feb 26, 2021 |
| DRSLTR · Letter to the SEC with a draft | Jan 27, 2021 |
| DRS/A · Draft registration statement, amended | Jan 27, 2021 |
| UPLOAD · Letter from the SEC | Jan 15, 2021 |
| DRS · Draft registration statement | Dec 18, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Jul 9, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cost of revenue | 114.2K | 534.9K | 516.7K | 98.6K | 42.5K | |||
| Gross profit | -114.2K | -534.9K | -516.7K | -98.6K | -42.5K | |||
| Research and development | 13.4M | 9.71M | 12.3M | 10.2M | 2.75M | 284.5K | 226.3K | 82.5K |
| Selling, general and administrative | 5.77M | 5.95M | 7.15B | 8.43M | 3.40M | 442.1K | 230.6K | 301.5K |
| Operating income | -28.0M | -15.7M | -19.4M | -18.6M | -6.15M | -726.6K | -456.9K | -384.0K |
| Depreciation and amortization | 13.4K | 90.9K | 123.5K | 98.6K | 42.5K | 0 | 42.5K | 384.0K |
| EBITDA | -28.0M | -15.6M | -19.3M | -18.5M | -6.11M | -726.6K | -414.4K | 0 |
| Interest expense | 6.62K | 26.8K | 55.9K | 32.0K | 95.1K | 394.6K | 157.0K | 0 |
| Income before tax | -34.4M | -16.8M | -18.5M | -17.6M | -6.84M | -2.34M | -607.2K | -453.4K |
| Income tax | 226.1K | 0 | 0 | 0 | 53.1K | 0 | 156.9K | -69.4K |
| Net income | -34.7M | -16.8M | -18.5M | -17.6M | -6.84M | -2.34M | -607.2K | -453.4K |
| Earnings per share, basic | -52.59 | -1,336.63 | -3,419.01 | -1,082.79 | -0.81 | -0.51 | -94.77 | |
| Earnings per share, diluted | -52.59 | -1,336.63 | -3,419.01 | -1,082.79 | -0.81 | -0.51 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 17.8M | 5.81M | 2.77M | 4.97M | 20.8M | 828.0K | 204.5K | 213.0K |
| Short-term investments | 9.41K | 9 | 3 | |||||
| Receivables | 3.25M | 360.2K | ||||||
| Inventory | 554.3K | |||||||
| Current assets | 22.0M | 7.09M | 4.46M | 7.38M | 22.7M | 831.2K | 204.5K | 214.6K |
| Property, plant and equipment | 370.7K | 51.6K | 120.7K | 208.6K | 206.3K | |||
| Goodwill | 25.7M | 0 | ||||||
| Total assets | 162.4M | 7.29M | 5.17M | 7.59M | 22.9M | 1.06M | 216.7K | 214.6K |
| Accounts payable | 3.12M | 2.58M | 2.33M | 4.12M | 2.02M | 369.2K | 27.3K | |
| Current liabilities | 3.49M | 2.77M | 3.49M | 4.35M | 2.53M | 404.9K | 62.9K | 117.7K |
| Long-term debt | 2.09M | 927.8K | ||||||
| Total debt | 38.3K | 450.6K | 2.09M | 927.8K | 471.9K | |||
| Total liabilities | 10.5M | 9.31M | 3.53M | 4.35M | 2.53M | 4.46M | 1.31M | 718.6K |
| Shareholders' equity | 10.3M | -2.02M | 1.64M | 3.24M | 20.4M | -3.41M | -1.10M | -504.0K |
| Shares outstanding | 917.0K | 36.8K | 19.0K | 16.2K | 12.9M | 4.64M | 6.41K | 192 |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -19.5M | -13.3M | -18.1M | -15.8M | -5.27M | -493.0K | -508.5K | -299.6K |
| Capital spending | -6.66K | -21.8K | -35.6K | -100.9K | -254.8K | -254.8K | -254.8K | -254.8K |
| Free cash flow | -19.5M | -13.4M | -18.1M | -15.9M | -5.52M | -493.0K | -508.5K | -299.6K |
| Cash from investing | -4.44K | -21.8K | -35.6K | -100.9K | -251.8K | -251.8K | -251.8K | -251.8K |
| Cash from financing | 31.5M | 16.4M | 15.9M | 5.99K | 25.5M | 1.12M | 500.0K | 512.4K |
| Dividends paid | -1.61B | -30.6M | ||||||
| Change in cash | 12.0M | 3.04M | -2.20M | -15.9M | 20.0M | 623.5K | -8.51K | 212.9K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| S-8 · Registration statement for employee plans | Nov 16, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 28, 2026 | Current report | SEC |
| 8-K · Current report | Oct 1, 2026 | Material contract | SEC |
| 8-K · Current report | Sep 28, 2026 | Current report | SEC |
| 3 · Initial statement of ownership | Sep 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 11, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 11, 2026 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 5, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 3 · Initial statement of ownership | Aug 5, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 3, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 3, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 28, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 28, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 28, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 27, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 23, 2026 | Big-stake notice | SEC |
| 424B3 · Prospectus | Jul 20, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Jul 20, 2026 | Offer document | SEC |
| 8-K · Current report | Jul 20, 2026 | Meeting outcome | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 17, 2026 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Jul 17, 2026 | Meeting notice | SEC |
| 8-K · Current report | Jul 17, 2026 | Current report | SEC |
| 8-K · Current report | Jul 2, 2026 | Current report | SEC |
| 8-K · Current report | Jun 18, 2026 | Current report | SEC |
| 8-K · Current report | Jun 3, 2026 | Current report | SEC |
| ARS · Annual report to shareholders | Jun 2, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Jun 2, 2026 | Meeting notice | SEC |
| 8-K · Current report | Jun 1, 2026 | Current report | SEC |
| DEFA14A · Additional proxy material | May 26, 2026 | Meeting notice | SEC |
| 8-K/A · Current report, amended | May 26, 2026 | Current report | SEC |
| 8-K · Current report | May 22, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | May 20, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | May 20, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 15, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 15, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | May 15, 2026 | Quarterly report | SEC |
| PRE 14A · Preliminary proxy statement | May 8, 2026 | Meeting notice | SEC |
| UPLOAD · Letter from the SEC | May 6, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 6, 2026 | Other filings | SEC |
| S-1 · Registration statement | Apr 30, 2026 | Offer document | SEC |
| S-3 · Registration statement | Apr 30, 2026 | Offer document | SEC |
| 10-K/A · Annual report, amended | Apr 30, 2026 | Annual report | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 20, 2026 | Big-stake notice | SEC |
| 10-K · Annual report | Apr 15, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 7, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 7, 2026 | Material contract | SEC |
| NT 10-K · Late filing notice | Mar 31, 2026 | Explanation request | SEC |
| DEFA14A · Additional proxy material | Mar 3, 2026 | Meeting notice | SEC |
| 8-K · Current report | Mar 3, 2026 | Financing | SEC |
| 8-K · Current report | Feb 23, 2026 | Current report | SEC |
| 8-K · Current report | Feb 5, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 7, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 6, 2026 | Current report | SEC |
| DEFA14A · Additional proxy material | Dec 23, 2025 | Meeting notice | SEC |
| 8-K/A · Current report, amended | Dec 23, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Dec 23, 2025 | Other filings | SEC |
| 3 · Initial statement of ownership | Dec 22, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 22, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 22, 2025 | Management or board change | SEC |
| CORRESP · Letter to the SEC | Dec 18, 2025 | Other filings | SEC |
| S-3 · Registration statement | Dec 12, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 11, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 14, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 10, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 28, 2025 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Oct 27, 2025 | Meeting notice | SEC |
| 8-K · Current report | Oct 27, 2025 | Current report | SEC |
| DEFA14A · Additional proxy material | Oct 17, 2025 | Meeting notice | SEC |
| 8-K/A · Current report, amended | Oct 17, 2025 | Material contract | SEC |
| SCHEDULE 13D · Big-stake notice | Oct 16, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Oct 14, 2025 | Current report | SEC |
| DEFA14A · Additional proxy material | Oct 8, 2025 | Meeting notice | SEC |
| 8-K/A · Current report, amended | Oct 8, 2025 | Material contract | SEC |
| DEFA14A · Additional proxy material | Oct 8, 2025 | Meeting notice | SEC |
| 8-K · Current report | Oct 8, 2025 | Acquisition or disposal | SEC |
| 8-K · Current report | Oct 3, 2025 | Material contract | SEC |
| 8-K · Current report | Sep 2, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2025 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | Jul 15, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jun 13, 2025 | Current report | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2025 | Current report | SEC |
| 8-K · Current report | May 5, 2025 | Current report | SEC |
| 8-K · Current report | May 2, 2025 | Meeting outcome | SEC |
| 10-K/A · Annual report, amended | Apr 30, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 21, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 21, 2025 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Apr 16, 2025 | Meeting notice | SEC |
| 10-K · Annual report | Apr 15, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 11, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 2, 2025 | Meeting notice | SEC |
| NT 10-K · Late filing notice | Mar 31, 2025 | Explanation request | SEC |
| 8-K · Current report | Mar 25, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Mar 25, 2025 | Offer document | SEC |
| SCHEDULE 13D · Big-stake notice | Mar 20, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Feb 25, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Feb 4, 2025 | Meeting notice | SEC |
| 8-K · Current report | Feb 4, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 3, 2025 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | Dec 30, 2024 | Meeting notice | SEC |
| 8-K · Current report | Dec 20, 2024 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Dec 19, 2024 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Dec 18, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 13, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 13, 2024 | Other filings | SEC |
| D | Dec 12, 2024 | Other filings | SEC |
| S-1 · Registration statement | Dec 6, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 2, 2024 | Material contract | SEC |
| 8-K · Current report | Nov 29, 2024 | Current report | SEC |
| 8-K · Current report | Nov 25, 2024 | Meeting outcome | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Nov 13, 2024 | Meeting notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 6, 2024 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Nov 6, 2024 | Meeting notice | SEC |
| 8-K · Current report | Nov 6, 2024 | Current report | SEC |
| DEF 14A · Proxy statement | Oct 28, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Oct 15, 2024 | Meeting notice | SEC |
| 8-K · Current report | Sep 27, 2024 | Current report | SEC |
| 8-K · Current report | Aug 28, 2024 | Current report | SEC |
| 8-K · Current report | Aug 16, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Aug 14, 2024 | Quarterly report | SEC |
| SC 13G · Big-stake notice | Jul 26, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jul 24, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Jul 24, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Jul 22, 2024 | Offer document | SEC |
| SC 13D · Big-stake notice | Jun 21, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 8-K/A · Current report, amended | Jun 14, 2024 | Meeting outcome | SEC |
| 8-K · Current report | Jun 13, 2024 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Jun 10, 2024 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Jun 7, 2024 | Meeting notice | SEC |
| 8-K · Current report | Jun 7, 2024 | Current report | SEC |
| DEFR14A | May 20, 2024 | Meeting notice | SEC |
| 8-K · Current report | May 15, 2024 | Current report | SEC |
| 10-Q · Quarterly report | May 15, 2024 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | May 13, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | May 10, 2024 | Meeting notice | SEC |
| 8-K · Current report | May 10, 2024 | Current report | SEC |
| ARS · Annual report to shareholders | Apr 29, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 29, 2024 | Meeting notice | SEC |
| 8-K · Current report | Apr 23, 2024 | Current report | SEC |
| 8-K · Current report | Apr 5, 2024 | Results | SEC |
| 10-K · Annual report | Apr 1, 2024 | Annual report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 15, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jan 31, 2024 | Current report | SEC |
| 8-K · Current report | Jan 22, 2024 | Material contract | SEC |
| 424B4 · Prospectus | Jan 19, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jan 19, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jan 18, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jan 17, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 17, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jan 17, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jan 16, 2024 | Other filings | SEC |
| 8-K · Current report | Jan 16, 2024 | Results | SEC |
| S-1 · Registration statement | Jan 11, 2024 | Offer document | SEC |
| 8-K · Current report | Jan 8, 2024 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Jan 4, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Dec 18, 2023 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Dec 8, 2023 | Meeting notice | SEC |
| 8-K · Current report | Dec 8, 2023 | Current report | SEC |
| SC 13G · Big-stake notice | Dec 7, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Dec 4, 2023 | Material contract | SEC |
| 424B5 · Prospectus | Dec 1, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2023 | Results | SEC |
| 8-K · Current report | Nov 9, 2023 | Current report | SEC |
| 8-K · Current report | Oct 27, 2023 | Current report | SEC |
| 424B5 · Prospectus | Oct 26, 2023 | Offer document | SEC |
| 8-K · Current report | Oct 24, 2023 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Oct 10, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2023 | Insider trade | SEC |
| 8-K · Current report | Sep 28, 2023 | Material contract | SEC |
| 424B4 · Prospectus | Sep 27, 2023 | Offer document | SEC |
| SC 13G · Big-stake notice | Sep 26, 2023 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Sep 26, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 25, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 25, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 25, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 25, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 22, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 22, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 22, 2023 | Other filings | SEC |
| S-1/A · Registration statement, amended | Sep 22, 2023 | Offer document | SEC |
| CORRESP · Letter to the SEC | Sep 15, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 15, 2023 | Other filings | SEC |
| S-1/A · Registration statement, amended | Sep 8, 2023 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Aug 31, 2023 | Other filings | SEC |
| S-1 · Registration statement | Aug 29, 2023 | Offer document | SEC |
| 8-K · Current report | Aug 24, 2023 | Current report | SEC |
This page holds 200 of 326 filings. Open Filings
Cap table
Built by 6ix from TransCode Therapeutics, Inc.’s releases · as of Nov 12, 2026
- Common shares
- 17,303,883
- Fully diluted
- 17,303,883
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 17,303,883 | Nov 12, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$0.86 · expire about Mar 2030 |
Share count over time
| Count | Shares |
|---|---|
| Nov 12, 2026 | 17,303,883 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Jack E Stover Other companies: Profusa, Inc. (Chief Executive Officer · Since at least Dec 20, 2021); Traws Pharma, Inc. (Director · Since at least May 18, 2016); PharmaCyte Biotech, Inc. (Director · Aug 15, 2022 – Aug 15, 2022 · Past); Antares Pharma Inc (President and CEO, Director · Jan 25, 2006 – May 14, 2008 · Past); Interpace Biosciences, Inc. (President and CEO, Director · Aug 3, 2005 – Mar 12, 2020 · Past) | Director · Since at least Dec 19, 2025 |
| Magda Marquet Other companies: First Tracks Biotherapeutics, Inc. (Director · Since at least Apr 1, 2026); Immix Biopharma, Inc. (Independent Director · Since at least Dec 15, 2021); AnaptysBio, Inc. (Director · Since at least Jan 18, 2021); Arcturus Therapeutics Holdings Inc. (Director · Since at least Jan 1, 2019); Pfenex Inc (Director · Feb 28, 2019 – Oct 1, 2020 · Past) | Director · Since at least Jul 8, 2021 |
| Elizabeth Czerepak Other companies: Delcath Systems, Inc. (DIRECTOR · Since at least Feb 14, 2020); Scilex Holding Company (See Remarks · Nov 10, 2022 – Jan 17, 2023 · Past); Sorrento Therapeutics, Inc. (EVP & Chief Financial Officer · Nov 15, 2021 – May 18, 2022 · Past); Spectrum Pharmaceuticals Inc (Director · Jun 19, 2019 – Jun 18, 2020 · Past) | CFO, Director · Since at least Oct 6, 2025 |
| Jack E. Stover Other companies: Profusa, Inc. (Director · Since at least Aug 20, 2026) | Director · Since at least Dec 22, 2025 |
| John Tattory Other companies: Windtree Therapeutics, Inc. (Interim CFO · Jul 28, 2016 – Jan 27, 2023 · Past) | Interim CFO · Since at least Sep 10, 2026 |
| Philippe Calais Other companies: CohBar Inc (Director · Jun 6, 2018 – May 31, 2019 · Past) | CEO · Since at least Jul 8, 2021 |
| Anna Moore | Chair of Scientific Advisory Board · Since at least Apr 27, 2026 |
| Erik Manting | Director · Since at least Jul 8, 2021 |
| Karrie Hilsinger | VP of Clinical Operations · Since at least Nov 4, 2026 |
| Michel Janicot | Consulting Head of Translational Science · Since at least Nov 17, 2025 |
All 14 people
| Person | Seat |
|---|---|
| Robert Michael Dudley | Chief Executive Officer, Director · Jul 8, 2021 – Sep 28, 2023 · Past |
| Tania Montgomery-Hammon | VP, Business Development · Since at least Oct 13, 2026 |
| Thomas A Fitzgerald | Chief Financial Officer, Director · Since at least Jul 8, 2021 |
| Zdravka Medarova | Cofounder/Chief Scientific Officer · Since at least Feb 1, 2022 |
Log in to ask 6ix AI your own questions about TransCode Therapeutics, Inc.